Sparcl1 and Atherosclerosis

References

• Li -J-J, Gao R-L. Should atherosclerosis be considered a cancer of the vascular wall? Medical Hypotheses. 2005;64(4):694–698. doi:10.1016/j.mehy.2004.11.043
   PubMed Web of Science ®Google Scholar
• Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and cancer; a resemblance with far-reaching implications. Arch Med Res. 2017;48:12–26.
   PubMed Web of Science ®Google Scholar
• Ouimet M. Autophagy in obesity and atherosclerosis: interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems. Biochim Biophys Acta. 2013;1831:1124–1133.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Zhang B, Gu J, Qian M, Niu L, Zhou H, Ghista D. Correlation between quantitative analysis of wall shear stress and intima-media thickness in atherosclerosis development in carotid arteries. Biomed Eng OnLine. 2017;16:137.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018;104(2):114–124. doi:10.1016/j.yexmp.2018.01.008
   PubMed Web of Science ®Google Scholar
• Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786. doi:10.1155/2013/152786
   PubMed Web of Science ®Google Scholar
• Lim S, Park S. Role of vascular smooth muscle cell in the inflammation of atherosclerosis. BMB Rep. 2014;47(1):1–7. doi:10.5483/bmbrep.2014.47.1.285
   PubMed Web of Science ®Google Scholar
• Hermida N, Balligand JL. Low-density lipoprotein-cholesterol-induced endothelial dysfunction and oxidative stress: the role of statins. Antioxid Redox Signal. 2014;20:1216–1237.
   PubMed Web of Science ®Google Scholar
• Mundi S, Massaro M, Scoditti E, et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res. 2018;114:35–52.
   PubMed Web of Science ®Google Scholar
• Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022;23:3346.
   PubMed Web of Science ®Google Scholar
• Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332–1339.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178–180.
   PubMed Web of Science ®Google Scholar
• Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis: a cancer of the blood vessels? Am J Clin Pathol. 2001;116(Suppl):S97–S107.
   PubMedGoogle Scholar
• Cordero A, Fácila L, García-Carrilero M, Gunturiz C, Montagud V, Núñez J. Breakfast habits in patients hospitalized for acute coronary syndrome. Rev Esp Cardiol. 2015;68:814–815.
   PubMed Web of Science ®Google Scholar
• de Nigris F, Sica V, Herrmann J, et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle. 2003;2:325–328.
   PubMed Web of Science ®Google Scholar
• Regensburger D, Tenkerian C, Pürzer V, et al. Matricellular protein SPARCL1 regulates blood vessel integrity and antagonizes inflammatory bowel disease. Inflam Bowel Dis. 2021;27:1491–1502.
   PubMed Web of Science ®Google Scholar
• Liu B, Xiang L, Ji J, et al. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest. 2021;131(20):e144801. doi:10.1172/JCI144801
   PubMed Web of Science ®Google Scholar
• Timofeeva AV, Goriunova LE, Khaspekov GL. [Comparative transcriptome analysis of human aorta atherosclerotic lesions and peripheral blood leukocytes from essential hypertension patients]. Kardiologiia. 2009;49(9):27–38. Russian.
   PubMed Web of Science ®Google Scholar
• Depuydt MAC, Prange KHM, Slenders L, et al. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. Circ Res. 2020;127(11):1437–1455. doi:10.1161/CIRCRESAHA.120.316770
   PubMed Web of Science ®Google Scholar
• Naschberger E, Liebl A, Schellerer VS, et al. Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma. J Clin Invest. 2016;126:4187–4204.
   PubMed Web of Science ®Google Scholar
• Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol. 2012;44:480–488.
   PubMed Web of Science ®Google Scholar
• Johnston IG, Paladino T, Gurd JW, Brown IR. Molecular cloning of SC1: a putative brain extracellular matrix glycoprotein showing partial similarity to osteonectin/BM40/SPARC. Neuron. 1990;4:165–176.
   PubMed Web of Science ®Google Scholar
• Schraml P, Shipman R, Stulz P, Ludwig CU. cDNA subtraction library construction using a magnet-assisted subtraction technique (MAST). Trends Genet. 1993;9:70–71.
   PubMed Web of Science ®Google Scholar
• Girard JP, Springer TA. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 1995;2:113–123.
   PubMed Web of Science ®Google Scholar
• Isler SG, Schenk S, Bendik I, et al. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol. 2001;18:521–526.
   PubMed Web of Science ®Google Scholar
• Nelson PS, Plymate SR, Wang K, et al. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res. 1998;58:232–236.
   PubMed Web of Science ®Google Scholar
• Bendik I, Schraml P, Ludwig CU. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res. 1998;58:626–629.
   PubMed Web of Science ®Google Scholar
• Ma Y, Xu Y, Li L. SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling. Exp Ther Med. 2018;16:3195–3201.
   PubMed Web of Science ®Google Scholar
• Han W, Cao F, Ding W, et al. Prognostic value of SPARCL1 in patients with colorectal cancer. Oncol Lett. 2018;15:1429–1434.
   PubMed Web of Science ®Google Scholar
• Maurer P, Hohenadl C, Hohenester E, Göhring W, Timpl R, Engel J. The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. J Mol Biol. 1995;253:347–357.
   PubMed Web of Science ®Google Scholar
• Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001;19(8):816–827.
   PubMedGoogle Scholar
• Vannahme C, Gösling S, Paulsson M, Maurer P, Hartmann U. Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochem J. 2003;373:805–814.
   PubMed Web of Science ®Google Scholar
• Ye H, Wang WG, Cao J, Hu XC. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma. Mol Med Rep. 2017;16:7784–7790.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu S, Yan Y, Li S, Tong H. SPARCL1 Influences Bovine Skeletal Muscle-Derived Satellite Cell Migration and Differentiation through an ITGB1-Mediated Signaling Pathway. Animals. 2020;10:1361.
   Web of Science ®Google Scholar
• Wang Y, Liu S, Yan Y, Li S, Tong H. SPARCL1 promotes C2C12 cell differentiation via BMP7-mediated BMP/TGF-β cell signaling pathway. Cell Death Dis. 2019;10:852.
   PubMed Web of Science ®Google Scholar
• Funk SE, Sage EH. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci U S A. 1991;88:2648–2652. doi:10.1073/pnas.88.7.2648
   PubMed Web of Science ®Google Scholar
• Claeskens A, Ongenae N, Neefs JM, et al. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 2000;82:1123–1130. doi:10.1054/bjoc.1999.1051
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang F, Feng L. The inhibition of HeLa cells proliferation through SPARCL1 mediated by SPP1. Cytotechnology. 2021;73:71–78. doi:10.1007/s10616-020-00443-2
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao J, Luan X, et al. SPARCL1 impedes trophoblast migration and invasion by down-regulating ERK phosphorylation and AP-1 production and altering EMT-related molecule expression. Placenta. 2020;89:33–41. doi:10.1016/j.placenta.2019.10.007
   PubMed Web of Science ®Google Scholar
• Girard JP, Springer TA. Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem. 1996;271(8):4511–4517. doi:10.1074/jbc.271.8.4511
   PubMed Web of Science ®Google Scholar
• Zhao SJ, Jiang YQ, Xu NW, et al. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/beta-catenin signaling through stabilization of the WNT-receptor complex. Oncogene. 2018;37:1049–1061. doi:10.1038/onc.2017.403
   PubMed Web of Science ®Google Scholar
• Meissburger B, Perdikari A, Moest H, Müller S, Geiger M, Wolfrum C. Regulation of adipogenesis by paracrine factors from adipose stromal-vascular fraction - a link to fat depot-specific differences, Biochim. Biophys Acta. 1861;2016:1121–1131. doi:10.1016/j.bbalip.2016.06.010
   Google Scholar
• Xiao C, Jin HG, Zhang LC, et al. Effects of SPARCL1 on the proliferation and differentiation of sheep preadipocytes. Adipocyte. 2021;10(1):658–669. doi:10.1080/21623945.2021.2010901
   PubMed Web of Science ®Google Scholar
• Kos K, Wong S, Tan B. Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. Diabetes. 2009;58(8):1780–1788. doi:10.2337/db09-0211
   PubMed Web of Science ®Google Scholar